Sevelamer-carbonate-Standard-生命科學(xué)試劑-MCE

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESevelamercarbonate(Standard)Cat.No.:HY-13995BRCASNo.:845273-93-0分?式:(C?H?N.C?H?ClO)x.xH?CO?作?靶點(diǎn):Others作?通路:Others儲(chǔ)存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Sevelamer(carbonate)(Standard)Sevelamer(carbonate)的分析標(biāo)準(zhǔn)品。本產(chǎn)品?于研究及分析應(yīng)?。Sevelamercarbonate?種具有?服活性的?鈣磷酸鹽結(jié)合劑(phosphatebindingagent)，?于慢性腎臟病(CKD)的?磷?癥研究。Sevelamercarbonate能有效降低體內(nèi)?磷?平，但對(duì)體內(nèi)?鈣、氯?平響極?。Sevelamercarbonate被認(rèn)為七氟?烯(HY-13995)的?種改進(jìn)的緩沖形式。REFERENCES[1].MaryMBarna,etal.Sevelamercarbonate.AnnPharmacother.2010Jan;44(1):127-34.[2].BarbaraRuggiero,etal.EffectsofSevelamerCarbonateinPatientsWithCKDandProteinuria:TheANSWERRandomizedTrial.AmJKidneyDis[3].SusanCSchiavi,etal.Npt2bdeletionattenuateshyperphosphatemiaassociatedwithCKD.JAmSocNephrol.2012Oct;23(10):1691-700.[4].YongshengYang,etal.EvaluationoftheInVitroEfficacyofSevelamerHydrochlorideandSevelamerCarbonate.JPharmSci.2016Feb;105(2):864-875[5].BennisY,etal.TheEffectofSevelameronSerumLevelsofGut-DerivedUremicToxins:ResultsfromInVitroExperimentsandAMulticenter,Double-Blind,Placebo-Controlled,RandomizedClinicalTrial.Toxins(Basel).2019May17;11(5):279.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792ax:0